CROI 2024 - CROI 2024

Workshop: Scott M. Hammer Workshop for New Investigators and Trainees

"Overview of the Scott M. Hammer Workshop for New Investigators and Trainees" by Serena S. Spudich Yale University, New Haven, CT, USA

Workshop: Scott M. Hammer Workshop for New Investigators and Trainees

"The Evolving HIV Landscape: From the Unimaginable to the Imaginable Cure" by Adam Castillejo The London Patient, London, UK

Workshop: Scott M. Hammer Workshop for New Investigators and Trainees

"Navigating Presentations in Molecular Virology at CROI 2024" by Frank Kirchhoff Ulm University Medical Center, Ulm, Germany

Workshop: Scott M. Hammer Workshop for New Investigators and Trainees

"Navigating Presentations in SARS-CoV-2 and HIV Immunology at CROI 2024" by Elizabeth Connick University of Arizona, Tucson, AZ, USA

Workshop: Scott M. Hammer Workshop for New Investigators and Trainees

"Navigating Presentations in HIV Cure at CROI 2024" by Afam A. Okoye Oregon Health and Sciences University, Portland, OR, USA

Workshop: Scott M. Hammer Workshop for New Investigators and Trainees

"Navigating Presentations in HIV Prevention at CROI 2024" by LaRon E Nelson Yale University, New Haven, CT, USA

Workshop: Scott M. Hammer Workshop for New Investigators and Trainees

"Navigating Presentations in Pediatric HIV at CROI 2024" by Jennifer Jao Northwestern University, Chicago, IL, USA

Workshop: Scott M. Hammer Workshop for New Investigators and Trainees

"From Early-Stage Investigator to Change Agent: Thoughts on Maximizing the Impact of Your Career" by Jeanne M. Marrazzo National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Workshop: Case-Based Workshop on Antiretroviral Therapy: A Panel Discussion

Claudia P. Cortes University of Chile, Santiago, Chile

Rajesh T. Gandhi Massachusetts General Hospital, Boston, MA, USA

"Overview of the Case-Based Workshop on Antiretroviral Therapy" by Claudia P. Cortes University of Chile, Santiago, Chile

"Overview of the Case-Based Workshop on Antiretroviral Therapy" by Rajesh T. Gandhi Massachusetts General Hospital, Boston, MA, USA

"Panel Discussion" by Anchalee Avihingsanon HIV-NAT, Bangkok, Thailand

"Panel Discussion" by Loice A. Ombajo University of Nairobi, Nairobi, Kenya

"Panel Discussion" by Anton L. Pozniak Chelsea and Westminster Hospital, London, UK

"Panel Discussion" by Janine M. Trevillyan Doherty Institute for Infection and Immunity, Melbourne, Australia

Workshop: Case-Based Workshop on the Liver and Its Complications

"Discussion with Audience Questions and Answers" by David L. Wyles Denver Health Medical Center, Denver, CO, USA

Annie Luetkemeyer University of California San Francisco, San Francisco, CA, USA

Workshop: Case-Based Workshop on the Liver and Its Complications

"Steatotic Liver Disease in Persons Living With HIV" by Jennifer C. Price University of California San Francisco, San Francisco, CA, USA

Workshop: Case-Based Workshop on the Liver and Its Complications

"Hepatitis Delta: What to Know, What to Do?" by Kathrin van Bremen University of Bonn, Bonn, Germany

Workshop: Case-Based Workshop on the Liver and Its Complications

"Cirrhosis Management" by Mazen Noureddin Houston Methodist Hospital, Houston, TX, USA

Workshop: Clinical Trial Design and Analysis

"Exploring Strategies to Measure and Understand Users' Preferences in HIV Prevention and Care" by Christine Tagliaferri Rael University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Workshop: Clinical Trial Design and Analysis

"Hybrid Effectiveness Implementation Studies: Unrecognized Challenges and Emerging Directions" by Elvin H. Geng Washington University in St Louis, St Louis, MO, USA

Workshop: Clinical Trial Design and Analysis

"Stopping Clinical Trials Early: When and Why" by Sally Hunsberger National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Workshop: Frontiers in Laboratory Technologies

"Cryoelectron Microscopy-Based Polyclonal Epitope Mapping (cryoEMPEM)" by Gabriel Ozorowski The Scripps Research Institute, La Jolla, CA, USA

Workshop: Frontiers in Laboratory Technologies

"A Spotlight on HIV: Visualizing Post-Entry Events by Correlative Light and Electron Microscopy" by Barbara Müller Heidelberg University, Heidelberg, Germany

Workshop: Frontiers in Laboratory Technologies

"Single-Virus Tracking: Capturing Fast, 3-Dimensional Viral Dynamics in Live Tissue Models" by Kevin Welsher Duke University, Durham, NC, USA

Workshop: Frontiers in Laboratory Technologies

"Single-Cell Multi-Omics of HIV Cellular Reservoirs" by Iain C. Clark University of California Berkeley, Berkeley, CA, USA

Opening Session

"Welcome from the CROI 2024 Program Committee Chair" by Landon Myer University of Cape Town, Cape Town, South Africa

Opening Session

"Recognition of Dr Adaora Adimora and Others We Have Lost" by Diane V. Havlir University of California San Francisco, San Francisco, CA, USA

Opening Session

"Introduction of the Bernard Fields Lecture" by Richard A. Koup National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Opening Session

"Modern Vaccinology: A Legacy of HIV Research" by Barney S. Graham Morehouse School of Medicine, Atlanta, GA, USA

Opening Session

"Introduction of the N'Galy-Mann Lecture" by Landon Myer University of Cape Town, Cape Town, South Africa

Opening Session

"Reflections on Ending Pediatric HIV: Back to Basics, Confront the Unexpected, Challenge Assumptions" by Dorothy Mbori-Ngacha United Nations Children Fund (former), Nairobi, Kenya

Opening Session

"Introduction of the Martin Delaney Presentation" by Grace Kumwenda AIDS Vaccine Advocacy Coalition (AVAC)

Opening Session

"Unveiling the Power of Uganda's LGBTIQ Advocacy in Shaping HIV Response and Health Care Access" by Frank Mugisha Sexual Minorities Uganda, SMUG

Opening Session

"Conclusion of Opening Session and Welcome to Opening Reception" by Nicolas Chomont Université de Montréal, Montreal, Canada

Monday Plenary Session

"CROI Program Committee Chair Welcome to Monday" by Landon Myer University of Cape Town, Cape Town, South Africa

Monday Plenary Session

"What's New in HIV Vaccines: Vaccine-Induced Immune Responses" by Juliana M. McElrath Fred Hutchison Cancer Center, Seattle, WA, USA

Elizabeth Connick University of Arizona, Tucson, AZ, USA

Monday Plenary Session

"Shall We Reach Human Papillomavirus Elimination in the Face of Inequity?" by Nelly R. Mugo Kenya Medical Research Institute, Nairobi, Kenya

Ruanne V. Barnabas Massachusetts General Hospital, Boston, MA, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1" by Russ P. Carstens Merck & Co., Inc.

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Antiviral Activity, Safety, and Pharmacokinetics of GS-1720: A Novel Weekly Oral InSTI" by Carl J. Fichtenbaum University of Cincinnati, Cincinnati, OH, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"VH3810109 (N6LS) in Adults With HIV-1 Who Are ART-Naive-: Phase IIa BANNER Efficacy Data" by Jan Losos ViiV Healthcare, Research Triangle Park, NC, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236" by Athe Tsibris Brigham and Women's Hospital, Boston, MA, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial" by Babafemi Taiwo Northwestern University, Chicago, IL, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab" by Joseph J. Eron University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies" by Boris D. Juelg Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Randomized Trial of Cabotegravir and Rilpivirine Long-Acting in Africa (CARES): Week 48 Results" by Nicholas Paton London School of Hygiene & Tropical Medicine, London, UK

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Phase I Safety, Tolerability and Pharmacokinetics of Tenofovir Alafenamide Implants in African Women" by Tanuja N. Gengiah Centre for the AIDS Programme of Research in South Africa, Durban, South Africa

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Final Results of ANRS 174 DOXYVAC: A Randomized Trial to Prevent STI in MSM on PrEP" by Jean-Michel G. Molina University of Paris-Est, Paris, France

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Sustained Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension" by Annie Luetkemeyer University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Doxycycline PEP: High Uptake and Significant Decline in STIs After Clinical Implementation" by Hyman M. Scott San Francisco Department of Public Health, San Francisco, CA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Doxy-PEP Associated With Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco" by Madeline Sankaran San Francisco Department of Public Health, San Francisco, CA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Site-Based HIV Testing Assay Performance for Cabotegravir and TDF-FTC PrEP Failure in HPTN 083" by Raphael J. Landovitz University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV" by Gillian Gillespie Merck & Co., Inc.,

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval" by Kelong Han GSK

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083" by Meredith Clement Louisiana State University, New Orleans, LA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: HIV Immunology and Vaccines

"INTRODUCTIONS (Part 1)" by

Oral Abstract: HIV Immunology and Vaccines

"Safety Profile and Immunogenicity of a Phase I Clinical Trial Using Germline-Targeting Trimer GT1.1" by Karlijn van der Straten Academic Medical Center, Amsterdam, Netherlands

Oral Abstract: HIV Immunology and Vaccines

"Vaccine Combining Slow-Delivery and Follicle-Targeting Improve Humoral and Germinal Center Responses" by Y. Jason Zhang Massachusetts Institute of Technology, Cambridge, MA, USA

Oral Abstract: HIV Immunology and Vaccines

"Multi-Specificity Is a Common Trait of HIV-1 Broad Neutralizing Capacity" by Alexandra Trkola University of Zurich, Zurich, Switzerland

Oral Abstract: HIV Immunology and Vaccines

"CD4 Binding Site Glycan-Deficient SHIVs Elicit Broadly Neutralizing Antibodies in Rhesus Macaques" by Daniel J. Morris University of Pennsylvania, Philadelphia, PA, USA

Oral Abstract: HIV Immunology and Vaccines

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: HIV Immunology and Vaccines

"INTRODUCTIONS (Part 2)" by

Oral Abstract: HIV Immunology and Vaccines

"MHC-E Presentation Mediates SIV-Specific NK Cell Responses in SIV-Infected Rhesus Macaques" by Philippe Rascle Duke University, Durham, NC, USA

Oral Abstract: HIV Immunology and Vaccines

"[18F]F-AraG PET Imaging Reveals Unique Tissue T-Cell Activation Patterns Across HIV Infection States" by Timothy J. Henrich University of California San Francisco, San Francisco, CA, USA

Oral Abstract: HIV Immunology and Vaccines

"Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI" by Preethi Krishnan AbbVie, Inc, North Chicago, IL, USA

Oral Abstract: HIV Immunology and Vaccines

"Live Single-Cycle SARS-CoV-2 Vaccine Elicits High Protection and Sterilizing Immunity" by Fabian Otte University of Basel, Basel, Switzerland

Oral Abstract: HIV Immunology and Vaccines

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Neuropathogenesis of HIV

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Neuropathogenesis of HIV

"Assessing the Contribution of Glial Activation to Cognitive Control and Declarative Memory in PWH" by Leah H. Rubin The Johns Hopkins University, Baltimore, MD, USA

Oral Abstract: Neuropathogenesis of HIV

"Associations Between Depressive Symptom Severity and Incident Stroke Among People With HIV" by Jimmy Ma University of Washington, Seattle, WA, USA

Oral Abstract: Neuropathogenesis of HIV

"Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection" by Meg Wilson University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Neuropathogenesis of HIV

"Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation" by Laura P. Kincer University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: Neuropathogenesis of HIV

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Neuropathogenesis of HIV

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Neuropathogenesis of HIV

"HIV Transcription Persists in the Brain of People With HIV and Viral Suppression" by Melissa J. Churchill RMIT University, Melbourne, Australia

Oral Abstract: Neuropathogenesis of HIV

"Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH" by Shelli Farhadian Yale University, New Haven, CT, USA

Oral Abstract: Neuropathogenesis of HIV

"Mini-Lecture on HIV Persistence in the CNS: Considerations for Current Cure Strategies" by Sharon R. Lewin University of Melbourne, Melbourne, Australia

Oral Abstract: Neuropathogenesis of HIV

"QUESTIONS AND ANSWERS (Part 2)" by

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Session Overview - Hazards Ahead: The Intersection of HIV and Substance Use" by Steffanie A. Strathdee University of California San Diego, San Diego, CA, USA

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Trends and Correlates of Methamphetamine Use Among Men Who Have Sex With Men in the US, 2014-2021" by Michael P. Barry University of Washington, Seattle, WA, USA

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Changes in HIV PrEP Awareness and Use Among PWID in 19 US Cities, 2018 and 2022" by Patrick Eustaquio Centers for Disease Control and Prevention, Atlanta, GA, USA

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Prescription Opioid Use and Disorder Among Older Adults With HIV in the US From 2008-2019" by Stephanie Shiau Rutgers University, Piscataway, NJ, USA

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Hazardous Alcohol Use Predicts Detectable Viremia Among Ugandan Women: A Prospective Analysis" by Amanda P. Miller San Diego State University

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Associations of Alcohol Consumption With Long-Term Mortality of ART-Naive Persons Seeking HIV Care" by Daniel Fuster Hospital Germans Trias i Pujol, Barcelona, Spain

Themed Discussion: Hazards Ahead: The Intersection of HIV and Substance Use

"Discussion with Audience Questions and Answers" by

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Session Overview - Is the Weight Over: GLP-1 Receptor Agonists Are Here" by Todd T. Brown The Johns Hopkins University, Baltimore, MD, USA

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Impact of Semaglutide on Weight Change Among People With HIV: A Stratified Analysis by Baseline BMI" by Heidi M. Crane University of Washington, Seattle, WA, USA

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy" by Allison Ross Eckard Medical University of South Carolina, Charleston, SC, USA

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study" by Grace L. Ditzenberger University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Themed Discussion: Is the Weight Over: GLP-1 Receptor Agonists Are Here

"Discussion with Audience Questions and Answers" by

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"Session Overview - PEP Prevention Toolbox: Do We Know How to Use It?" by Sigal Yawetz Brigham and Women's Hospital, Boston, MA, USA

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"HIV Post-Exposure Prophylaxis Prescription Trends: United States, 2013-2022" by Mary R. Tanner Centers for Disease Control and Prevention, Atlanta, GA, USA

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"BIC/FTC/TAF as HIV PEP Was Well-Tolerated With High Adherence and No Seroconversions" by Darrell H. S. Tan St Michael's Hospital, Toronto, Canada

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"A Matter of Time: Factors Associated With Delayed nPEP Initiation" by Nicholas Brian Bana ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"PrEP Following PEP: An Effective HIV Risk-Reduction Strategy" by Gary Whitlock Chelsea and Westminster NHS Foundation Trust, London, UK

Themed Discussion: PEP Prevention Toolbox: Do We Know How to Use It?

"Discussion with Audience Questions and Answers" by

Themed Discussion: Viral Rebound

"Session Overview - Viral Rebound" by Javier Martinez-Picado IrsiCaixa Institute for AIDS Research, Badalona, Spain

Themed Discussion: Viral Rebound

"Common T-Cell Features Predicting Time to Rebound in Interventional and Non-Interventional Treatment" by Tongcui Ma Gladstone Institutes, San Francisco, CA, USA

Themed Discussion: Viral Rebound

"The Fraction of HIV Reservoir Variants Neutralized by Autologous IgG Correlates With Time to Rebound" by Mauro A. Garcia The Johns Hopkins University, Baltimore, MD, USA

Themed Discussion: Viral Rebound

"Intact HIV Reservoir Levels Are Stable After Short-Term ART Interruption" by Prerana Shrestha Brigham and Women's Hospital, Boston, MA, USA

Themed Discussion: Viral Rebound

"Dynamics of the Intact HIV Reservoir During ART Following Analytical Treatment Interruption" by Maegan R. Manning National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Themed Discussion: Viral Rebound

"Immune Responses and HIV Reservoir Evolution From Pre-ART to 5 Years Into Post-Treatment Control" by Leah Carrere Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Themed Discussion: Viral Rebound

"Discussion with Audience Questions and Answers" by

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"INTRODUCTIONS (Part 1)" by

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"COVID Incidence and Severity in Persons With Reinfection vs Post-Vaccination Breakthrough Infection" by Adeel A. Butt Weill Cornell Medicine, New York, NY, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"MRNA Vaccine Versus Hybrid Immunity Against COVID-19 Among People With HIV During Omicron Wave" by Asa Tapley Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency" by Yijia Li University of Pittsburgh, Pittsburgh, PA, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"Analysis of Emergent SARS-CoV-2 Antiviral Resistance and Its Association With Virologic Rebound" by Trevor J. Tamura Brigham and Women's Hospital, Boston, MA, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"Molnupiravir Does Not Increase 3CLpro Resistance Mutations When Co-Administered With Nirmatrelvir/r" by Shuntai Zhou University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"Mini-Lecture: Progress in Understanding the Mechanisms of Long COVID" by Annukka A. R. Antar The Johns Hopkins University, Baltimore, MD, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"Multimodal Assessment of Antigen Persistence in the Post-Acute Phase of SARS-CoV-2 Infection" by Michael J. Peluso University of California San Francisco, San Francisco, CA, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"QUESTIONS AND ANSWERS (Part 2)" by

Symposium: Living Into Young Adulthood With Perinatal HIV

"Discussion with Audience Questions and Answers" by Allison L. Agwu Johns Hopkins University

Victor Reyes Howard University, Washington, DC, USA

Symposium: Living Into Young Adulthood With Perinatal HIV

"Epidemiology of Perinatally Acquired HIV Among Adolescents and Young Adults" by Mutsawashe F. Bwakura-Dangarembizi University of Zimbabwe, Harare, Zimbabwe

Symposium: Living Into Young Adulthood With Perinatal HIV

"Historic Evolution of HIV and Mental Well-Being Among Adults Living With Perinatally Acquired HIV" by Ezer Kang Howard University, Washington, DC, USA

Symposium: Living Into Young Adulthood With Perinatal HIV

"Cardiometabolic Risks and Complications: Adolescents and Young Adults With Perinatally Acquired HIV" by Sahera Dirajlal-Fargo Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA

Symposium: The HIV Vaccine Journey: Don't Stop Believin'

"Discussion with Audience Questions and Answers" by Georgia D. Tomaras Duke University, Durham, NC, USA

Leonidas Stamatatos Fred Hutchison Cancer Center, Seattle, WA, USA

Symposium: The HIV Vaccine Journey: Don't Stop Believin'

"Neutralizing Antibody Protection: Where Do We Go From Here?" by Yunda Huang Fred Hutchison Cancer Center, Seattle, WA, USA

Symposium: The HIV Vaccine Journey: Don't Stop Believin'

"Germline Targeting Strategies to Get On the Road Again" by Rogier W. Sanders Academic Medical Center, Amsterdam, Netherlands

Symposium: The HIV Vaccine Journey: Don't Stop Believin'

"Novel Immunization Strategies to Move on Down the Road" by Darrell Irvine Massachusetts Institute of Technology, Cambridge, MA, USA

Symposium: The Return of Syphilis

"Discussion with Audience Questions and Answers" by Jodie A. Dionne University of Alabama at Birmingham, Birmingham, AL, USA

Alex de Voux University of Cape Town, Cape Town, South Africa

Symposium: The Return of Syphilis

"Why Can't We Do Better at Diagnosing Syphilis?" by Ina Park University of California San Francisco, San Francisco, CA, USA

Symposium: The Return of Syphilis

"The Burgeoning Epidemic of Congenital Syphilis" by Angelica Espinosa Miranda Ministry of Health, Brasilia, Brazil

Symposium: The Return of Syphilis

"Syphilis Management Conundrums" by Khalil G. Ghanem The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Tuesday Plenary Session

"CROI Program Committee Chair Welcome to Tuesday" by Nicolas Chomont Université de Montréal, Montreal, Canada

Tuesday Plenary Session

"HIV Assembly, Maturation Inhibitors, and Drug Resistance" by Eric O. Freed National Cancer Institute, Frederick, MD, USA

Stuart J.D. Neil King's College London, London, United Kingdom

Tuesday Plenary Session

"Accelerating Tuberculosis Elimination: Short-Course Prevention and Treatment" by Vidya Mave Byramjee Jeejeebhoy Government Medical College - Johns Hopkins > Research Program, Pune, India

Constance A. Benson University of California San Diego, La Jolla, CA, USA

Oral Abstract: Combating Complications of HIV

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Combating Complications of HIV

"Treatment of Prehypertension in People Living With HIV: A Randomized Controlled Trial" by Lily D. Yan Weill Cornell Medicine, New York, NY, USA

Oral Abstract: Combating Complications of HIV

"A Nurse-Led Strategy Improves Blood Pressure and Cholesterol in People With HIV: The EXTRA-CVD Trial" by Chris T. Longenecker University of Washington, Seattle, WA, USA

Oral Abstract: Combating Complications of HIV

"Community Health Worker-Facilitated Telehealth for Severe Hypertension Care in Kenya and Uganda" by Matt Hickey University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Combating Complications of HIV

"Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE" by Márton Kolossváry Massachusetts General Hospital

Oral Abstract: Combating Complications of HIV

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Combating Complications of HIV

"Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE" by Kristine M. Erlandson University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Oral Abstract: Combating Complications of HIV

"Lung Function, HIV and Mortality: Analyses From the AIDS Linked to the Intravenous Experience Cohort" by Sarath Raju The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: Combating Complications of HIV

"Prostate Cancer Characteristics and Outcomes for Veterans With HIV in the Antiretroviral Era" by Keith Sigel Icahn School of Medicine at Mt Sinai, New York, NY, USA

Oral Abstract: Combating Complications of HIV

"InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change" by Rebecca Abelman University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Combating Complications of HIV

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Hepatitis and Tuberculosis

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Hepatitis and Tuberculosis

"Simultaneous Initiation in ART-Naive PWH of DTG-Based ART & 3HP Maintains Efficacious DTG Levels" by Ethel D. Weld The Johns Hopkins University, Baltimore, MD, USA

Oral Abstract: Hepatitis and Tuberculosis

"Early Bactericidal Activity of the Alpibectir-Ethionamide (AlpE) Combination Against Tuberculosis" by Jeantelle Du Preez TASK Applied Science, Cape Town, South Africa

Oral Abstract: Hepatitis and Tuberculosis

"NAFLD and Advanced Fibrosis Are Common in Adults With HIV and Associated With Unique Histology" by Jennifer C. Price University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Hepatitis and Tuberculosis

"Semaglutide Reduces Metabolic-Associated Steatotic Liver Disease in People With HIV: The SLIM LIVER" by Jordan E. Lake University of Texas at Houston, Houston, TX, USA

Oral Abstract: Hepatitis and Tuberculosis

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Hepatitis and Tuberculosis

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Hepatitis and Tuberculosis

"Trends in HIV and HCV Prevention Efforts and Incidence Among People Who Inject Drugs in Baltimore" by Eshan U. Patel The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Oral Abstract: Hepatitis and Tuberculosis

"Preclinical Pharmacokinetic Assessment of a Hepatitis C Virus Long-Acting Injectable Formulation" by Usman Arshad University of Liverpool, Liverpool, UK

Oral Abstract: Hepatitis and Tuberculosis

"Intrahepatic HDV Activity Is Fueled by Integrated HBV DNA-Derived HBs Independently From cccDNA Size" by Stefano D'Anna University of Rome Tor Vergata, Rome, Italy

Oral Abstract: Hepatitis and Tuberculosis

"A 4-Month Regimen of Quabodepistat, Delamanid, and Bedaquiline for Pulmonary TB: Interim Results" by Simbarashe Takuva Otsuka Novel Products GmbH

Oral Abstract: Hepatitis and Tuberculosis

"Provisional Results From a 3-month Clofazimine/Rifapentine-Containing Regimen for Drug-Sensitive TB" by John Metcalfe University of California, San Francisco

Oral Abstract: Hepatitis and Tuberculosis

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Association of State-Level PrEP Coverage and State-Level HIV Diagnoses, US, 2012-2021" by Patrick S. Sullivan Emory University, Atlanta, GA, USA

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"HIV Incidence in Users of HIV Preexposure Prophylaxis in Australia: A Whole-of-Population Analysis" by Nicholas A. Medland University of New South Wales, Sydney, Australia

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"High PrEP Uptake and Adherence Measured Objectively Among Young African Women in the INSIGHT Cohort" by Brenda G. Mirembe Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Safety of Dapivirine Vaginal Ring and Oral PrEP for HIV Prevention in the Second Trimester" by Felix Mhlanga University of Zimbabwe College of Health Sciences Clinical Trials Research Centre

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Phone Calls for PrEP Persistence in Kenyan Women in Postabortal Care: A Cluster Randomized Trial" by Renee Heffron University of Alabama at Birmingham, Birmingham, AL, USA

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Adherence Benchmarks for TFV-DP in DBS and PBMCs for African Women Using FTC/TDF PrEP" by Kenneth K. Mugwanya University of Washington, Seattle, WA, USA

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"HIV Incidence in the INSIGHT Cohort of African Women: Recency Testing and Prospective Follow-Up" by Irene Mukui University of Washington, Seattle, WA, USA

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Randomized Trial of SEARCH Dynamic Choice HIV Prevention Including Injectable Cabotegravir (CAB-LA)" by Moses R. Kamya Makerere University, Kampala, Uganda

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"HIV-1 Transcription Start Sites Usage and Its Impact on Unspliced RNA Functions In Vivo" by Saiful Islam National Institutes of Health, Frederick, MD, USA

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Investigation of the Functional Role of DDX42 in HIV-1 Viral RNA Splicing" by Xiao Lei The Rockefeller University, New York, NY, USA

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Structural Basis of Translation Inhibition by MERS-CoV Nsp1 Reveals a Conserved Mechanism for β-CoVs" by Michael Vetick Yale University, New Haven, CT, USA

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"“Traitor”-Virus-Guided Discovery of Novel Antiviral Factors" by Caterina Prelli Bozzo Ulm University Medical Center, Ulm, Germany

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Immunoregulatory Pathways Predict Mortality More Strongly in People With Versus Without HIV" by Samuel R. Schnittman Massachusetts General Hospital, Boston, MA, USA

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"HIV-1 Soluble gp120 Is Associated With Immune Dysfunction in Individuals on Antiretroviral Therapy" by Mehdi Benlarbi Université de Montréal, Montreal, Canada

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Rapid Emergence and Adaptive Evolution of SARS-CoV-2 Variants in Advanced HIV Infection" by Sung Hee Ko National Institutes of Health

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Temperature-Dependent SARS-CoV-2 Spike-ACE2 Interaction Is Associated With Viral Transmission" by Andrés Finzi Université de Montréal, Montreal, Canada

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"IFNα2 Autoantibodies Post-SARS-CoV-2 Wave 1 in India Are Associated With Lower Omicron Symptomology" by Enrico Bravo King's College London, London, United Kingdom

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"QUESTIONS AND ANSWERS (Part 2)" by

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Session Overview - Anal Cancer Screening and Pathogenesis" by Timothy J. Wilkin Weill Cornell Medicine, New York, NY, USA

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Evaluation of the Performance of Different High-Resolution Anoscopy Triage Strategies in MSM LWH" by Eugenio Nelson Cavallari Sapienza University of Rome, Rome, Italy

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Anal Self-Sampling Is Suitable for Anal Cancer Screening Among Men Who Have Sex With Men in Togo" by Charlotte Charpentier Hôpital Bichat-Claude-Bernard, Paris, France

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Clinical Predictors and Outcomes of Anal Cancer for People With HIV in an Inception Cohort" by Edward Cachay University of California San Diego, San Diego, CA, USA

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Long-Term ART Is Not Associated With Reduced Anogenital Cancer Risk: A Case-Cohort Study" by Maanasa Mendu Harvard University, Cambridge, MA, USA

Themed Discussion: Anal Cancer Screening and Pathogenesis

"Discussion with Audience Questions and Answers" by

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Session Overview - Hypertension and HIV: Pregnancy, Postpartum, and Beyond" by Elizabeth M. Stringer University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Maternal HIV Is Associated With Lower Risk of Preeclampsia Among Zambian Women" by Katelyn J. Rittenhouse University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Hypertension in Pregnant Persons by HIV Status and by DTG vs EFV Use in Botswana" by Denise L. Jacobson Harvard University, Cambridge, MA, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Association of HIV and Dolutegravir With Changes in Blood Pressure During Pregnancy and Postpartum" by Jennifer Jao Northwestern University, Chicago, IL, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Pregnancy History Affects Age-Related Comorbidity Burden in US Women With and Without HIV" by Lauren F. Collins Emory University, Atlanta, GA, USA

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"DTG Versus EFV Initiation in Pregnancy Is Not Associated With Postpartum Blood Pressure" by Thokozile R. Malaba University of Cape Town, Cape Town, South Africa

Themed Discussion: Hypertension and HIV: Pregnancy, Postpartum, and Beyond

"Discussion with Audience Questions and Answers" by

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Session Overview - Persistent Immune Activation and Inflammation During Antiretroviral Therapy" by Frank Maldarelli National Cancer Institute, Frederick, MD, USA

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Low-Level HIV Viremia Affects T-Cell Activation and Senescence in InSTI Era" by Violeta Lara Aguilar Institute of Health Carlos III, Madrid, Spain

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Ultra-Low Level HIV p24 Production as a Driver of Immune Activation in Individuals Treated with ART" by Enrico Richter Bonn University Hospital, Bonn, Germany

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"CARD8 Activation in Myeloid Cells as a Driver of Inflammation in HIV Infection" by Marilia R. Pinzone Washington University in St Louis, St Louis, MO, USA

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Increased Immune Activation Following Acute Sleep Deprivation in People With HIV on ART" by Bernard J. C. Macatangay University of Pittsburgh School of Medicine

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Immunosuppressive Effects of LLDT-8 in ART-Treated SIV-Infected Rhesus Macaques" by Xiaosheng Liu Tsinghua University, Beijing, China

Themed Discussion: Persistent Immune Activation and Inflammation During Antiretroviral Therapy

"Discussion with Audience Questions and Answers" by

Themed Discussion: Violence, Displacement, and HIV

"Session Overview - Violence, Displacement, and HIV" by Mesfin Teklu Tessema International Rescue Committee

Themed Discussion: Violence, Displacement, and HIV

"Impact of Natural Disasters on HIV Risks and Viral Suppression in Ugandan Fishing Village" by Hadijja Nakawooya Rakai Health Sciences Program, Kalisizo, Uganda

Themed Discussion: Violence, Displacement, and HIV

"The Need to Address Violence for PrEP Uptake Among Adolescent Girls and Young Women in South Africa" by Courtney P. Bonner RTI International, Research Triangle Park, NC, USA

Themed Discussion: Violence, Displacement, and HIV

"Prevalence of HIV and Viral Load Suppression Among Refugees in Uganda, October to December 2021" by Jessica E. Justman Columbia University Medical Center, New York, NY, USA

Themed Discussion: Violence, Displacement, and HIV

"Violence and HIV Sexual Risk Behaviours Among Adolescent Girls and Young Women: Eswatini Experience" by Siphiwe M. Shongwe-Gama ICAP at Columbia University, Mbabane, Swaziland

Themed Discussion: Violence, Displacement, and HIV

"Discussion with Audience Questions and Answers" by

Symposium: Impact on HIV Care and Services Among Refugees, Displaced Persons, and Marginalized Populations

"Overview of the Global Displacement Crisis" by Mesfin Teklu Tessema International Rescue Committee

"Panelist Reflections on the Global Displacement Crisis" by

"Meeting the Needs of People Affected by HIV From Ukraine" by Milosz Parczewski Pomeranian Medical University, Szczecin, Poland

"Protracted Consequences of Displacement: A Perspective From Latin America" by Omar M. Sued Pan American Health Organization, Washington, DC, USA

"Lived Experience From Ukraine" by Yana Panfilova Teenergizer, Kyiv, Ukraine

"Roundtable Discussion" by Wafaa El-Sadr Columbia University, New York, NY, USA

"Roundtable Discussion" by Mesfin Teklu Tessema International Rescue Committee

"Roundtable Discussion" by Carlos del Rio Emory University, Atlanta, GA, USA

"Roundtable Discussion" by Milosz Parczewski Pomeranian Medical University, Szczecin, Poland

"Roundtable Discussion" by Yana Panfilova Teenergizer, Kyiv, Ukraine

"Roundtable Discussion" by Omar M. Sued Pan American Health Organization, Washington, DC, USA

Symposium: New Frontiers in Hepatitis B

"Novel Markers of Hepatitis B: Clinical Utility for New Treatment Strategies" by Fabien Zoulim L’Université Claude Bernard Lyon 1, Lyon, France

Symposium: New Frontiers in Hepatitis B

"Advances in HBV Immunotherapy: The Beginning of the End?" by Adam Gehring University of Toronto, Toronto, Canada

Symposium: New Frontiers in Hepatitis B

"How New WHO Guidance Can Transform Hepatitis B in Sub-Saharan Africa" by Olufunmilayo Lesi World Health Organization, Geneva, Switzerland

Symposium: New Frontiers in Hepatitis B

"International Perspectives on Hepatitis B: Panel Discussion" by David L. Thomas The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Weston Spurr Person with Lived Experience, Denver, Colorado

Anna S. Lok University of Michigan, Ann Arbor, MI, USA

Fabien Zoulim L’Université Claude Bernard Lyon 1, Lyon, France

Chien-Ching Hung National Taiwan University Hospital, Taipei City, Taiwan

Hugo Perazzo Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil

Olufunmilayo Lesi World Health Organization, Geneva, Switzerland

Symposium: Not Just a Pretty Shape: HIV Assembly to Disassembly

"Discussion with Audience Questions and Answers" by Owen Pornillos University of Utah, Salt Lake City, UT, USA

Melissa Kane University of Pittsburgh, Pittsburgh, PA, USA

Symposium: Not Just a Pretty Shape: HIV Assembly to Disassembly

"HIV-1 Genome Packaging During Virion Assembly: Selecting the Right RNA" by Wei-Shau Hu National Cancer Institute, Frederick, MD, USA

Symposium: Not Just a Pretty Shape: HIV Assembly to Disassembly

"Virion Maturation: Folding Into the Right Shape" by Mamuka Kvaratskhelia University of Colorado, Aurora, CO, USA

Symposium: Not Just a Pretty Shape: HIV Assembly to Disassembly

"Virion Disassembly: Keeping it Together Until the Right Moment" by Gregory Towers University College London, London, UK

Symposium: Roundtable on DoxyPEP: Ready or Not…

"Discussion with Audience Questions and Answers" by Kenneth Ngure Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

Michael Traeger Burnet Institute, Melbourne, VIC, Australia

Symposium: Roundtable on DoxyPEP: Ready or Not…

"Introduction to DoxyPEP: Understanding the Issues" by Chase A. Cannon University of Washington, Seattle, WA, USA

Symposium: Roundtable on DoxyPEP: Ready or Not…

"DoxyPEP: Should We Worry About Antimicrobial Resistance?" by Beatrice B.S.L. Bercot St Louis Hospital, Paris, France

Symposium: Roundtable on DoxyPEP: Ready or Not…

"Implementation of DoxyPEP: Challenges and Opportunities" by Stephanie E. Cohen San Francisco Department of Public Health, San Francisco, CA, USA

Wednesday Plenary Session

"CROI Program Committee Chair Welcome to Wednesday" by Diane V. Havlir University of California San Francisco, San Francisco, CA, USA

Wednesday Plenary Session

"The End of Oral? How Long-Acting Formulations Are Changing the Management of Infectious Diseases" by Charles W. Flexner The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Joseph J. Eron University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Wednesday Plenary Session

"Diagnostics 4.0: The Future of Diagnostics for HIV and Related Infections" by Nitika P. Pai McGill University, Montreal, Canada

Jonathan Mermin Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"INTRODUCTIONS (Part 1)" by

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"High Rates of Viral Suppression in Pregnancy Drop Postpartum in South African Women on TLD" by Elaine J. Abrams Columbia University, New York, NY, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"Hypertension in a Randomized Trial of DTG vs EFV-Based ART in Pregnant and Postpartum Women" by Risa Hoffman University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"ART-Free HIV-1 Remission in Very Early Treated Children: Results From IMPAACT P1115" by Deborah Persaud The Johns Hopkins University School of Medicine

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"GIVE MOVE: Randomized Trial on Genotype-Informed Management of Viremia in Children and Adolescents" by Jennifer A. Brown University Hospital Basel, Basel, Switzerland

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"INTRODUCTIONS (Part 2)" by

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART" by Hilda A. Mujuru University of Zimbabwe

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"Emerging Dolutegravir Resistance Among Children Being Investigated for Treatment Failure in Malawi" by George Bello International Training and Education Center for Health

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"Long-Acting Cabotegravir Plus Rilpivirine In Adolescents With HIV: Week 24 IMPAACT 2017(MOCHA) Study" by Aditya Gaur St Jude Children's Research Hospital, Memphis, TN, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"SEARCH: Youth Intervention Impact on Symptoms of Depression in East African Youth Living With HIV" by James Ayieko Kenya Medical Research Institute, Nairobi, Kenya

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"Role of Community-Level Factors in Declines in HIV Incidence and Prevalence Among Rakai Adolescents" by John S. Santelli Columbia University Medical Center, New York, NY, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: HIV Reservoir and Cure Strategies

"INTRODUCTIONS (Part 1)" by

Oral Abstract: HIV Reservoir and Cure Strategies

"Selection of Epigenetically Privileged HIV-1 Proviruses During Treatment With Panobinostat and IFNα" by Marie Armani-Tourret Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"Role of Cytoskeleton and Adhesion in a Rare Subset of HIV-Infected Cells That Resist CTL" by Louise Leyre Weill Cornell Medicine, New York, NY, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"Sex-Specific Innate Immune Selection in Vertical HIV Transmission and cART-Free Aviraemia in Males" by Gabriela Z.L. Cromhout University of KwaZulu-Natal

Oral Abstract: HIV Reservoir and Cure Strategies

"Sex-Based Differences in HIV-1 Reservoir Profile in Individuals With Long-Term ART Suppression" by Toong Seng Tan Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: HIV Reservoir and Cure Strategies

"AAV-Expressed HIV IgG Biologics Enable Durable ART-Free Viral Control in Infant Macaques" by Mauricio A. Martins University of Florida, Gainesville, FL, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"Broadly Neutralizing Antibody-Secreting T Cells and CAR-Ts Potently Suppress In Vivo HIV Infection" by Hang Su Albert Einstein College of Medicine, Bronx, NY, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"Autologous Neutralizing Antibodies Contribute to Virus Control in a Subset of PWH Treated With bNAbs" by Katharine J. Bar University of Pennsylvania, Philadelphia, PA, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"A T Cell-Targeting mRNA SIV Vaccine Extends Time to Rebound and Enhances Post-ART Viral Control" by Benjamin Varco-Merth Oregon Health and Sciences University, Portland, OR, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"IL-15/IL-15RA Cytokine Therapy Enhances Control of Viral Rebound in SIV-Infected Macaques" by Vijayakumar Velu Emory University, Atlanta, GA, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Together Take Me Home: Launch of a National HIV Self-Test Distribution Program, March-December 2023" by Kevin P. Delaney Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Incidence of Health Facility Switching and HIV Viral Rebound in Uganda: A Population-Based Study" by Joseph G. Rosen The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Improving Posthospital Outcomes in People With HIV: A Multicenter Randomized Trial in Tanzania" by Serena Koenig Harvard Medical School, Boston, MA, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Lakeside Combined HIV and Schistosomiasis Services in Malawian Fishermen: A Cluster Randomized Trial" by Augustine T. Choko Liverpool School of Tropical Medicine, Liverpool, UK

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"What Are the Outcomes for Established Clients Enrolled in DSD During the First 3 Years on ART?" by Amy N. Huber University of the Witwatersrand, Johannesburg, South Africa

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Opt-Out HIV Testing in Emergency Departments Successfully Addresses Key Gaps in Testing" by Lisa Hamzah St George's University Hospitals NHS Foundation Trust

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Few Discordant HIV Ag/Ab and RNA Test Results Among Persons in a National Cohort of PrEP Users" by Weiming Zhu Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Missed Opportunities to Prevent Congenital Syphilis in Antenatal PrEP Services in South Africa" by Dvora L. Joseph Davey University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Investigation of HIV Transmission Associated With Receipt of Vampire Facials: New Mexico, 2018-2023" by Anna M. Behar Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Trends in Black-White Disparities in HIV Diagnosis: 2017-2021, United States" by André Dailey Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Estimating Lifetime Risk of a Diagnosis of HIV Infection Among MSM: United States, 2017-2021" by Sonia Singh Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Quantifying HIV-1 Transmission Between People Who Inject Drugs and Other Populations in Kenya" by Hanley Kingston University of Washington, Seattle, WA, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Demographics Are Crucial to Interpret 95-95-95 Targets in African Populations With High ART Coverage" by Andrea Brizzi Imperial College London, London, UK

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"High Prevalence of Advanced HIV Disease in Sub-Saharan Africa: An Analysis of 11 Household Surveys" by Dominik Stelzle World Health Organization, Geneva, Switzerland

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Low-Level Viremia Trends Among Persons With HIV: A 5-Country Analysis From 10 PHIA Surveys" by Jessica E. Justman Columbia University Medical Center, New York, NY, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"A New 2023-2024 Mpox Outbreak in Brazil: Lessons From a Reemerging Neglected Disease" by Mayara Secco Torres da Silva Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Vaccine Effectiveness Against COVID In-Hospital Mortality by HIV Status Across SARS-CoV-2 Variants" by Seth Inzaule World Health Organization, Geneva, Switzerland

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"INTRODUCTIONS" by

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study" by Amy Colson Community Resource Initiative

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"HepB-CpG Vaccine Is Superior to HepB-alum in People With HIV and Prior Vaccine Nonresponse: A5379" by Kristen Marks Weill Cornell Medicine, New York, NY, USA

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"Efficacy, Safety, and Immunogenicity of H56:IC31 Vaccine for Prevention of Recurrent TB" by Alvaro Borges Statens Serum Institut

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"Efficacy, Safety, and PK of BIC/FTC/TAF in Adults With HIV and Tuberculosis on Rifampicin at Week 24" by Anushka Naidoo Center for the AIDS Programme of Research in South Africa

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"Long-Acting Injectable CAB/RPV is Superior to Oral ART in PWH With Adherence Challenges: ACTG A5359" by Aadia I. Rana University of Alabama at Birmingham, Birmingham, AL, USA

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"QUESTIONS AND ANSWERS" by

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Session Overview - Dolutegravir Resistance in Resource-Limited Settings" by Gert U. van Zyl Stellenbosch University, Cape Town, South Africa

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Viremia and Drug Resistance 2 Years After Routine Switching to Dolutegravir-Based First-Line ART" by Richard J. Lessells KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"DTG Resistance in Patients with Previous ARV Experience and Viremia in Kenya Receiving DTG-Based ART" by Leonard Kingwara Ministry of Health, Nairobi, Kenya

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Emerging Dolutegravir Resistance in Lesotho" by Niklaus D. Labhardt University of Basel, Basel, Switzerland

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Resistance to Second-Generation InSTIs in Mexican PLWH: Emergence of the R263K Mutant" by Luis Enrique Soto Ramírez incmnsz

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Virologic Outcomes With Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure" by Ying Zhao University of Cape Town, Cape Town, South Africa

Themed Discussion: Dolutegravir Resistance in Resource-Limited Settings

"Discussion with Audience Questions and Answers" by

Themed Discussion: Mucosal Immunity to HIV

"Session Overview - Mucosal Immunity to HIV" by Barbara L. Shacklett University of California Davis, Davis, CA, USA

Themed Discussion: Mucosal Immunity to HIV

"A Novel Non-Invasive Approach to Sample Female Genital Tract Immune Cell Populations" by M. Quinn Peters Seattle Children's Research Institute, Seattle, WA, USA

Themed Discussion: Mucosal Immunity to HIV

"Identification of Innate Lymphoid Cell Subsets in the Human Female Genital Tract That Respond to HIV" by Alexandra E. Werner Tufts University, Boston, MA, USA

Themed Discussion: Mucosal Immunity to HIV

"The Cervicovaginal Neutrophil Protein CRISP3 Is a Correlate of HIV Protection" by Adam Burgener Case Western Reserve University, Cleveland, OH, USA

Themed Discussion: Mucosal Immunity to HIV

"CD101 Variants Are Associated With Lower Levels of Genital HIV-Inhibiting and Tissue Repair Factors" by Sarah C. Vick Fred Hutchison Cancer Center, Seattle, WA, USA

Themed Discussion: Mucosal Immunity to HIV

"Synergistic Effects of HIV, HPV, and Polyomaviruses on Interferon Response in Male Anal Mucosa" by Matteo Fracella Sapienza University of Rome, Rome, Italy

Themed Discussion: Mucosal Immunity to HIV

"Discussion with Audience Questions and Answers" by

Themed Discussion: Novel Interventions in HIV Programming

"Session Overview - Novel Interventions in HIV Programming" by Angeli Achrekar Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland

Themed Discussion: Novel Interventions in HIV Programming

"Automated Condom Distribution for HIV Prevention: Mwanza, Tanzania, 2021-2023" by Julie C Franks Columbia University Medical Center, New York, NY, USA

Themed Discussion: Novel Interventions in HIV Programming

"Cost-Effectiveness of an Agricultural Intervention Among Adults With HIV and Their Children in Kenya" by Assurah W. Elly Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya

Themed Discussion: Novel Interventions in HIV Programming

"Persistence on Contraception and PrEP in Hair Salons in South Africa" by Ingrid V. Bassett Massachusetts General Hospital, Boston, MA, USA

Themed Discussion: Novel Interventions in HIV Programming

"Availability of Onsite Substance Use Disorder Services in HIV Facilities by Urbanicity in the US" by Kashif Iqbal Centers for Disease Control and Prevention, Atlanta, GA, USA

Themed Discussion: Novel Interventions in HIV Programming

"Discussion with Audience Questions and Answers" by

Themed Discussion: Strategies for an HIV Cure

"Session Overview - Strategies for an HIV Cure" by Susana Valente The Scripps Research Institute, La Jolla, CA, USA

Themed Discussion: Strategies for an HIV Cure

"Potent HIV Latency Reversal by Lipid Nanoparticles Encapsulating HIV Tat mRNA" by Bridget M. Fisher University of Melbourne, Melbourne, Australia

Themed Discussion: Strategies for an HIV Cure

"CD4-Targeted mRNA Delivery of Tat Reverses HIV-1 Latency" by Edward Kreider University of Pennsylvania, Philadelphia, PA, USA

Themed Discussion: Strategies for an HIV Cure

"Nanoparticle Delivery of Tat Synergizes With Latency Reversal Agents to Express HIV Antigen" by Shane D. Falcinelli University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Themed Discussion: Strategies for an HIV Cure

"Ruxolitinib-Mediated HIV-1 Reservoir Decay in A5336 Phase IIa Trial" by Monica D. Reece Emory University, Atlanta, GA, USA

Themed Discussion: Strategies for an HIV Cure

"Short-Term BCL-2 Inhibition at ART Initiation Transiently Reduces SIV Reservoir in Rhesus Macaques" by Tomas Raul Wiche Salinas Emory University, Atlanta, GA, USA

Themed Discussion: Strategies for an HIV Cure

"Discussion with Audience Questions and Answers" by

Symposium: Follow Your Heart: Managing Cardiovascular Disease Risk in HIV

"Overview of the REPRIEVE Trial" by Steven K. Grinspoon Massachusetts General Hospital, Boston, MA, USA

Symposium: Follow Your Heart: Managing Cardiovascular Disease Risk in HIV

"Sex Differences in Atherosclerotic CVD Risks and Mechanisms: Insights From REPRIEVE" by Markella V. Zanni Massachusetts General Hospital, Boston, MA, USA

Symposium: Follow Your Heart: Managing Cardiovascular Disease Risk in HIV

"Immunomodulation and Cardiovascular Disease: Lessons Learned From HIV" by Priscilla Y. Hsue University of California San Francisco, San Francisco, CA, USA

Symposium: Follow Your Heart: Managing Cardiovascular Disease Risk in HIV

"Implications for Implementing CVD Risk Prevention Strategies for Low- and Middle-Income Countries" by Mpiko Ntsekhe University of Cape Town, Cape Town, South Africa

Symposium: Follow Your Heart: Managing Cardiovascular Disease Risk in HIV

"Panel Discussion" by

Symposium: Innovations in Intervention: Toward an HIV Cure

"Discussion with Audience Questions and Answers" by María Buzón Vall d'Hebron Research Institute, Barcelona, Spain

Alberto Bosque George Washington University

Symposium: Innovations in Intervention: Toward an HIV Cure

"From Mechanisms to Therapeutics: Eliminating HIV-Infected Cells by the CARD8 Inflammasome" by Liang Shan Washington University in St Louis, St Louis, MO, USA

Symposium: Innovations in Intervention: Toward an HIV Cure

"From Mechanisms to Therapeutics: TACK Molecules Kill HIV-Infected Cells Through Inflammasome Activation" by Tracy L. Diamond Merck & Co., Inc., Rahway, NJ, USA

Symposium: Innovations in Intervention: Toward an HIV Cure

"From Transcriptomics to Therapeutics: A Host Restriction Factor That Targets HIV Expression" by Rasmi Thomas Walter Reed Army Institute of Research, Silver Spring, MD, USA

Symposium: Innovations in Intervention: Toward an HIV Cure

"From Structure to Therapeutics: CD4 Mimetics 'Open' Env and Sensitize HIV-1-Infected Cells to ADCC" by Andrés Finzi Université de Montréal, Montreal, Canada

Symposium: Promise and Pitfalls of Biomedical Prevention: Beyond Phase III

"Introduction" by Linda-Gail Bekker Desmond Tutu HIV Foundation, Cape Town, South Africa

Bruno Spire Institut National de la Santé et de la Recherche Médicale, Marseille, France

Symposium: Promise and Pitfalls of Biomedical Prevention: Beyond Phase III

"Why Is Cabotegravir Rollout So Slow?" by Rupa R. Patel Centers for Disease Control and Prevention, Atlanta, GA, USA

Symposium: Promise and Pitfalls of Biomedical Prevention: Beyond Phase III

"The Ring Comes Full Circle: Navigating the Complex Landscape of Biomedical Prevention Post-Phase III" by Leila E. Mansoor Centre for the AIDS Programme of Research in South Africa, Durban, South Africa

Symposium: Promise and Pitfalls of Biomedical Prevention: Beyond Phase III

"Challenging the Dogma of Event-Driven PrEP" by Jenell Stewart Hennepin Healthcare Research Institute, Minneapolis, MN, USA

Symposium: Promise and Pitfalls of Biomedical Prevention: Beyond Phase III

"Panel Discussion" by Linda-Gail Bekker Desmond Tutu HIV Foundation, Cape Town, South Africa

Bruno Spire Institut National de la Santé et de la Recherche Médicale, Marseille, France